Insulin-like growth factor-1 receptor expression in thymic malignancies Journal Article
| Authors: | Girard, N.; Teruya-Feldstein, J.; Payabyab, E. C.; Riely, G. J.; Rusch, V. W.; Kris, M. G.; Zakowski, M. F. |
| Article Title: | Insulin-like growth factor-1 receptor expression in thymic malignancies |
| Abstract: | Introduction: Thymic epithelial tumors are rare mediastinal malignancies that can be invasive and difficult to treat. Insulin-like growth factor-1 receptor (IGF-1R) is a transmembrane receptor implicated in the regulation of cell metabolism, growth, and survival. As higher levels of IGF-1R protein expression may be associated with relative sensitivity to anti-IGF-1R antibody treatment, we investigated IGF-1R expression in thymic malignancies. Methods: Sixty-three thymic tumors (56 thymomas and seven thymic carcinomas) were analyzed for total IGF-1R expression using immunohistochemistry with a specific antibody (clone G11, Roche-Ventana, Tucson, AZ). Expression levels were correlated with relevant clinical and pathologic variables, including epidermal growth factor receptor and KIT expression, and patient outcome. Results: IGF-1R staining was negative in 13 (21%) cases, low (1+) in 20 (32%) cases, moderate (2+) in 20 (32%) cases, and high (3+) in 10 (16%) cases. Moderate to high IGF-1R staining was observed in 6 of 7 (86%) thymic carcinomas and in 24 of 56 (43%) thymomas (p = 0.039). Moderate to high IGF-1R staining was associated with high epidermal growth factor receptor staining (p = 0.015). By multivariate analysis, only tumor stage and histologic type were significant prognostic factors on time to progression (hazard ratio [HR] = 4.12, 95% confidence interval [CI]: 1.98-14.23; p = 0.010 and HR = 2.79, 95% CI: 1.62-12.50; p = 0.018, respectively). There was no association between IGF-1R expression and time to progression (HR = 3.07, 95% CI: 0.38-24.59; p = 0.291). Conclusion: A majority of thymic malignancies display moderate to high expression of IGF-1R. The lack of preclinical models prevented us to further study the functional consequences of anti-IGF-1R therapy in this setting. However, given correlations in other cancers, these data support the evaluation of anti-IGF-1R inhibitors in thymic tumors. © 2010 by the International Association for the Study of Lung Cancer. |
| Keywords: | immunohistochemistry; adult; human tissue; protein expression; aged; survival rate; retrospective studies; human cell; major clinical study; carcinoma, squamous cell; cancer staging; neoplasm staging; cell survival; stem cell factor receptor; proto-oncogene proteins c-kit; cell growth; epidermal growth factor receptor; tumor markers, biological; receptor, epidermal growth factor; somatomedin c receptor; receptor, igf type 1; immunoenzyme techniques; tissue array analysis; kit; tissue microarray; egfr; thymoma; cell metabolism; thymic carcinoma; thymus neoplasms; thymus cancer; igf-1r |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 5 |
| Issue: | 9 |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2010-09-01 |
| Start Page: | 1439 |
| End Page: | 1446 |
| Language: | English |
| DOI: | 10.1097/JTO.0b013e3181e392a8 |
| PUBMED: | 20736806 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 20 April 2011" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work